From Contract to Patient: Reducing Speed-to-Launch Barriers in Direct-to-Patient Programs
As pharmaceutical companies expand direct-to-patient (DTP) strategies, many continue to face lengthy implementation timelines driven by fragmented technology environments, custom integrations, and complex program requirements. These delays can slow patient access, extend the time between program approval and first prescription fulfillment, and limit a brand's ability to respond quickly to market opportunities.
In this webinar, industry leaders will discuss the technology and operational factors that influence the speed, scalability, and success of DTP program launches. Panelists will explore the challenges of balancing customization with efficiency while examining how configurable platforms, reusable technology components, and API-enabled architectures can help organizations reduce implementation complexity, accelerate deployment, and support repeatable growth across brands and therapeutic areas without sacrificing flexibility or patient experience.
Attendees Will Gain Insights Into:
- Why traditional hub and DTP implementation models often struggle to scale efficiently
- The tradeoffs between custom-built programs and configurable infrastructure approaches
- How organizations are reducing time-to-launch while maintaining program flexibility
- The role of modular, API-enabled infrastructure in supporting repeatable deployment across brands and therapeutic areas
- Key considerations for evaluating DTP infrastructure investments and long-term scalability
Speakers
